OBJECTIVE: To observe the effect of Tongguan Capsule (TGC), a Chinese herbal preparation for supplementing qi and activating blood circulation, in patients after percutaneous coronary intervention (PCI) with qi-deficiency and blood stasis syndrome. METHODS:One hundred patients after successful PCI operation were assigned to two groups, 50 in each group. Western routine therapy with anti-thrombosis and anti-coagulant agents were applied in all patients before, during and after operation, while to the patients in the treated group, TGC was given additionally. The therapeutic course for both groups was one month. The efficacy was evaluated by observing the effect on angina pectoris, main TCM syndromes and scores of qi-deficiency syndrome and blood stasis syndrome at 3 time points (the day before, 3 days and 30 days after operation). RESULTS: The total effective rate in relieving angina pectoris was 96.0% (48/50) in the treated group and 92.0% (46/50) in the control group, showing insignificant difference between them (P > 0.05). The score of qi-deficiency in both groups raised 3 days after PCI as compared with that before PCI, but showed no statistical significance (P > 0.05); 30 days after PCI, it increased in the control group, as compared with that before PCI (P < 0.05). The score of blood stasis syndrome significantly lowered at the 3rd and the 30th day after PCI in both groups as compared with before PCI, showing statistical significance (P < 0.05); while in comparing the value at the 3rd day with that at the 30th day, the difference showed significance in the treated group but not in the control group (P < 0.05); and comparison between the two groups at the 30th day showed it was much lower in the treated group (P < 0.05). CONCLUSION:TGC could significantly improve the clinical symptoms of qi-deficiency and blood stasis syndrome in patients after PCI.
RCT Entities:
OBJECTIVE: To observe the effect of Tongguan Capsule (TGC), a Chinese herbal preparation for supplementing qi and activating blood circulation, in patients after percutaneous coronary intervention (PCI) with qi-deficiency and blood stasis syndrome. METHODS: One hundred patients after successful PCI operation were assigned to two groups, 50 in each group. Western routine therapy with anti-thrombosis and anti-coagulant agents were applied in all patients before, during and after operation, while to the patients in the treated group, TGC was given additionally. The therapeutic course for both groups was one month. The efficacy was evaluated by observing the effect on angina pectoris, main TCM syndromes and scores of qi-deficiency syndrome and blood stasis syndrome at 3 time points (the day before, 3 days and 30 days after operation). RESULTS: The total effective rate in relieving angina pectoris was 96.0% (48/50) in the treated group and 92.0% (46/50) in the control group, showing insignificant difference between them (P > 0.05). The score of qi-deficiency in both groups raised 3 days after PCI as compared with that before PCI, but showed no statistical significance (P > 0.05); 30 days after PCI, it increased in the control group, as compared with that before PCI (P < 0.05). The score of blood stasis syndrome significantly lowered at the 3rd and the 30th day after PCI in both groups as compared with before PCI, showing statistical significance (P < 0.05); while in comparing the value at the 3rd day with that at the 30th day, the difference showed significance in the treated group but not in the control group (P < 0.05); and comparison between the two groups at the 30th day showed it was much lower in the treated group (P < 0.05). CONCLUSION: TGC could significantly improve the clinical symptoms of qi-deficiency and blood stasis syndrome in patients after PCI.